Gilead Sciences Inc. announced final results from the Phase 3 MYR301 study, highlighting the effects of bulevirtide as a treatment for chronic hepatitis delta virus $(HDV)$. The study revealed that 36% of adults treated with bulevirtide maintained virologic suppression for nearly two years after stopping treatment, having achieved undetectable HDV RNA at the end of treatment. The data also showed that 90% of those who achieved undetectability at 96 weeks of treatment remained undetectable for almost two years post-treatment. Bulevirtide, available in a 2 mg dose, is currently approved in the European Economic Area, the UK, Switzerland, and Australia, but not in the U.S. The findings underscore the potential of bulevirtide to provide a durable response and improve outcomes for individuals living with chronic HDV.